Articles tagged "Adverse effects"

2016 American Transplant Congress
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.
A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
¹U of Cinncinati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Experience with bortezomib (BTZ) antibody mediated rejection (AMR) therapy has progressively increased over the past few years. The BTZ toxicity profile in the transplant…
2016 American Transplant Congress
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, South Carolina.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to assess the impact of…
2016 American Transplant Congress
Simulating Alternative Bayesian Criteria to Identify Transplant Center Performance Outliers.
J. Schold,¹ C. Miller,¹ M. Henry,² L. Buccini,¹ S. Flechner,¹ D. Goldfarb,¹ E. Poggio,¹ K. Andreoni.³
¹Cleveland Clinic, Cleveland, OH; ²Ohio State University, Columbus, OH; ³University of Florida, Gainesville, FL.
The newly constructed Bayesian models to evaluate transplant center performance were implemented in 2014. The rates and impact of the assumptions used for flagging centers…
2016 American Transplant Congress
High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients.
D. Berglund,¹ D. Schladt,² K. Sanghavi,¹ W. Guan,¹ B. Wu,¹ C. Dorr,³ R. Remmel,¹ R. Mannon,⁴ A. Matas,¹ W. Oetting,¹ A. Israni,³ P. Jacobson,¹ DeKAF Genomics Investigators.
¹UofMN, Mpls; ²MMRF, Mpls; ³HCMC, Mpls; ⁴UAB, Birmingham.
Kidney tx recipients carry a high burden of comorbidities, and some of the medications for these conditions have genetic predictors of efficacy and toxicity. These…
2016 American Transplant Congress
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.
S. Yeager, A. Carlson, C. Truax, N. Kenyon, F. Ahmed, J. Corbett, F. Shihab, L. Smith.
University of Utah Health Care, Salt Lake City, UT.
Although everolimus is an attractive option for conversion therapy in pancreas tx pts that experience SE's of commonly used immunosuppression, TAC and MPA, there is…
2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
¹University of Utah, Salt Lake City, UT; ²University of Southern California, Los Angeles, CA; ³Barnabas Health, West Orange, NJ; ⁴Novartis Pharmaceuticals Corporation, East Hannover, NJ; ⁵California Pacific Medical Center, San Francisco, CA; ⁶Vanderbilt University, Nashville, TN.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…
2016 American Transplant Congress
In Their Own Words: Living Kidney Donors Who Develop Kidney Failure.
L. Ross,¹ C. Halverson,² J. Wang,¹ M. Poulson,³ J. Karlin,⁴ M. Crowley-Matoka.⁵
¹U Chicago, Chicago, IL; ²Anthropology, U Chicago, Chicago, IL; ³Georgetown U, Washington, DC; ⁴Family Medicine, UCSF, San Francisco, CA; ⁵Medical Humanities, Northwestern U, Chicago, IL.
Background: Psychosocial data about living kidney donation have been collected for almost five decades. The results are almost uniformly positive, even in the early years…
2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospitals, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…
2016 American Transplant Congress
Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation.
J. Kallini,² A. Gabr,² R. Salem,² R. Lewandowski,² T. Baker.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²Division of Interventional Oncology, Northwestern University, Chicago, IL.
Background: Pretransplant liver directed therapy has emerged as standard of care for patients with end stage liver disease complicated by unresectable hepatocellular cancer. The aim…
2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
M. Willicombe, D. Goodall, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…